Rising Trend of Young Onset Dementia Patients with Substantial Social Challenges and High Economic Burden  

Researchers from the National Neuroscience Institute (NNI) have reported increasing numbers of patients diagnosed with Young Onset Dementia (YOD), with data suggesting that they are likely to face significant social challenges and lifestyle changes brought upon by high economic burden. Their findings highlight the need for special programmes that offer employment and financial assistance to support patients and their families. [Read more]


NNI Researchers Identify Protein That Provokes Aggression of Brain Tumours 

Scientists from the Neuro-Oncology Programme at the National Neuroscience Institute (NNI) have identified the ST3Gal1 gene as a trigger that promotes the aggressive spreading of tumour cells in the brain. This study was published in Journal of the National Cancer Institute (ranked 8th out of 211 leading journals under the category of Oncology), and was led by Associate Professor Ang Beng Ti, Head and Senior Consultant, Department of Neurosurgery, NNI (SGH campus), and Dr Carol Tang, Senior Research Scientist. The team also included Associate Professor Nguan Soon Tan from Nanyang Technological University and Dr Joanna Holbrook from the Singapore Institute for Clinical Sciences, A*STAR. 

The team has developed a molecular signature that can identify poorly surviving patients who demonstrate an increase in ST3Gal1 activity. This molecular signature – a set of genes, proteins, genetic variants or other variables - can be used as a biomarker to gain valuable insight into understanding the tumour behaviour, importantly because the molecular signature has outperformed other clinical indicators such as age, tumour grade and patient functional status, which traditionally determine patient outcome. [Read more]


Hovid and NNI Collaborate To Research Palm Tocotrienols and its Neuroprotective Effects in Parkinson Disease

Hovid Berhad and National Neuroscience Institute signed a Memorandum of Understanding (MOU) to embark on research to study the neuroprotective effects of palm tocotrienols in Parkinson Disease (PD). The MOU was signed at the Academia, an iconic landmark on the Singapore General Hospital (SGH) campus that is home to SingHealth’s research laboratories, education and training facilities.

Palm tocotrienol research has been identified as an area of national importance in Malaysia, being part of a National Key Economic Area (NKEA) under the government’s Economic Transformation Program (ETP). Significant strides have been made in clinical investigations that have shown palm tocotrienols’ therapeutics and preventative effects for neurological diseases in the areas of stroke and dementia, which show that 200mg of palm tocotrienols, when taken twice daily, is able to protect human nerves from neurological damage. [Read more]


NUS and NNI to Deepen Collaborative Research on Ageing and Neurological Diseases

The National University of Singapore (NUS) and National Neuroscience Institute (NNI) signed a Memorandum of Understanding (MOU) to establish a working relationship for joint research programmes and cross-institutional collaborations in Neurobiology and Ageing. The partnership seeks to drive research programmes to improve diagnosis and prevention of age-related neurological diseases. The MOU was signed at the opening ceremony of the 2015 Singapore Institute for Neurotechnology (SINAPSE) – NNI Symposium. [Read more]


NNI Researchers Discover Novel Function of Protein Linked to Alzheimer’s Disease

A research team led by the National Neuroscience Institute (NNI) has uncovered a novel function of the Amyloid Precursor Protein (APP), one of the main pathogenic culprits of Alzheimer’s disease. This discovery may help researchers understand how the protein goes awry in the brains of Alzheimer’s disease patients, and potentially paves the way for the development of innovative therapeutics to improve the brain function of dementia patients. [Read more]


Singapore's Largest Neuroscience Research Institute Launched to Advance Care for Disorders Like Stroke and Dementia

The National Neuroscience Research Institute Singapore (NNRIS) – a joint venture by the National Neuroscience Institute (NNI) and Duke-NUS Graduate Medical School – has been launched to improve treatment and seek cures through research for brain and nervous system disorders such as stroke, Parkinson disease and dementia.

The NNRIS will be Singapore’s largest institute specialising in neuroscience research, bringing together more than 200 neurologists, neuroscientists and research professionals from NNI and Duke-NUS to work in collaboration. The Institute will consolidate expertise from the two organisations’ neuroscience research programmes, integrate research resources for common use, as well as develop a new research facility for neurobehavioural experiments. These will yield a more targeted, focused approach to neurological research in Singapore. [Read more]


NNI & NUS Researchers Discover Green Tea Component Helps Protect against PD

NNI and researchers at NUS YLLSoM have identified a component in green tea called EGCG that provides cellular protection against Parkinson disease. The study found that EGCG-treated fruit flies exhibited much better movement ability and showed significant preservation of their brain neurons, compared to untreated flies. The discovery may lead to the potential invention of medication that can reverse the debilitating effects of PD. [Read more]



Joint Study by NNI, NUS & SICS Discover the Role of New Tumour Suppressor

NNI researchers together with NUS Yong Loo Lin School of Medicine (YLLSoM), and Singapore Institute for Clinical Sciences (SICS) at A*STAR, has discovered the role of a new tumour suppressor known as Parkin in brain cancer which could shed insights into why certain brain tumours are more aggressive than others. Patients who have a higher tumour suppressor in a type of brain cancer cells - glioma - tend to survive longer with lower tumour grades. Using animal models, researchers found that animals are able to survive longer after the restoration of Parkin in brain cancer cells as it reduces the brain tumour size “significantly”. The study, which began in 2009, was published in the May 2012 edition of Cancer Research




You are a vital partner in our endeavours to improve patients’ lives. Find out how!

Copyright © 2013. All rights reserved.